生物科技公司 PrimeGen US 周三表示，将通过与空白支票公司 DT Cloud Star Acquisition 达成的15 亿美元交易，在美国实现上市。
该交易预计于2026 年下半年完成。合并后的公司将以 PrimeGen US 名义运营，并计划在纳斯达克交易所挂牌上市。
此次交易落地之际，企业对通过特殊目的收购公司（SPAC）合并实现上市的兴趣再度升温，将其作为传统上市方式的替代选择。
SPAC 作为空壳公司运作，通过首次公开募股（IPO）筹集资金，随后与私人控股公司合并，将其推向公开市场。
PrimeGen 是一家专注于干细胞疗法研发的生物科技公司，主打针对急性肝损伤及相关重症的治疗方案。
责任编辑：郭明煜
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.